Silver Book Fact

Impact of a healthy lifestyle on age-related macular degeneration (AMD)

A study exploring the impact of a healthy lifestyle on age-related macular degeneration (AMD) found that women whose diets were the healthiest (scored on the 2005 Healthy Eating Index) had 46% lower odds of developing early AMD than those whose diets were the least healthy.  It also found that women with the most physical activity had 54% lower odds for early AMD compared to those with the least amount of physical activity.

Mares JA, Voland RP, Sondel SA, et al. Healthy Lifestyles Related to Subsequent Prevalence of Age-Related Macular Degeneration. Arch Ophthalmol. 2011; 129(4): 322-326. http://archopht.jamanetwork.com/article.aspx?articleid=427181

Reference

Title
Healthy Lifestyles Related to Subsequent Prevalence of Age-Related Macular Degeneration
Publication
Arch Ophthalmol
Publication Date
2011
Authors
Mares JA, Voland RP, Sondel SA, et al
Volume & Issue
Volume 129, Issue 4
Pages
322-326
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Between 2008 and 2009, the number of Americans age 65-74 who reported trouble seeing (even with glasses or contacts) decreased from 14.3% to 10.3%.  The number of Americans age 75…  
  • Gene transfer process treatment for diabetic retinopathy
    A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient–…  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.